A molecular perspective on the potential benefits of metformin for the treatment of inflammatory skin disorders

Abstract

Due to its anti‐hyperglycemic effect, metformin is the first‐line medication for the treatment of type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a very wide range of pharmacological properties and reports of its therapeutic effect on diseases including inflammation and cancer are increasing. Numerous research groups have reported that metformin has beneficial effects on a variety of inflammatory skin disorders including psoriasis, acanthosis nigricans, acne, hidradenitis suppurativa, and allergic contact dermatitis. According to these reports, in addition to the well‐known action of metformin, that is, its anti-hyperglycemic effect, NF‐kB inhibition and the resulting alteration to the cytokine network may be the potential targets of metformin. Its anti‐hyperandrogenism effect has also been confirmed as the major action of metformin in some inflammatory skin diseases. Moreover, novel regulatory mechanisms, including autophagy and antioxidant processes, have been suggested as promising mechanisms of action for metformin in inflammatory skin disorders.